白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2008年
2期
114-118
,共5页
时云飞%周春菊%刘翠苓%李敏%黄欣%董格红%黄远洁%尹文娟%杨艳丽%刘芳%马晓龙%杜鹃%高子芬
時雲飛%週春菊%劉翠苓%李敏%黃訢%董格紅%黃遠潔%尹文娟%楊豔麗%劉芳%馬曉龍%杜鵑%高子芬
시운비%주춘국%류취령%리민%황흔%동격홍%황원길%윤문연%양염려%류방%마효룡%두견%고자분
淋巴瘤,T细胞%免疫组织化学%病毒调控蛋白质类%预后
淋巴瘤,T細胞%免疫組織化學%病毒調控蛋白質類%預後
림파류,T세포%면역조직화학%병독조공단백질류%예후
Lymphoma,T-cell%Immunohistochemistry%Viral regulatory proteins%Prognosis
目的 研究原发系统型间变性大细胞淋巴瘤(S-ALCL)间变性淋巴瘤激酶(ALK-1)蛋白及细胞毒性相关蛋白TIA-1和granzyme B表达情况,探讨其与预后的关系.方法 收集北京大学医学部病理学系淋巴瘤研究室及北京儿童医院确诊S-ALCL病例51例,常规形态观察,复习及补充必要免疫组化标记以核实诊断.采用SP法检测ALK-1蛋白及细胞毒相关蛋白TIA-1和granzyme B的表达.收集临床资料并完善随访.结果 51例S-ALCL中,36例(63%)ALK-1蛋白阳性.47例S-ALCL中20例(42.55%)granzyme B蛋白阳性.28例行TIA-1蛋白检测,22例(81.48%)阳性.51例中有随访资料者共44例(86.27%),生存时间0.5～66个月.ALK-1阳性病例、granzyme B阴性病例预后较好.而TIA-1的表达与预后无关.COX比例风险回归分析表明ALK-1、granzyme B的表达及Ann-Arbor分期对预后有统计学意义(P＜0.05).结论 ALK-1与granzyme B均是独立的预后指标,有助于S-ALCL病例的预后判断.
目的 研究原髮繫統型間變性大細胞淋巴瘤(S-ALCL)間變性淋巴瘤激酶(ALK-1)蛋白及細胞毒性相關蛋白TIA-1和granzyme B錶達情況,探討其與預後的關繫.方法 收集北京大學醫學部病理學繫淋巴瘤研究室及北京兒童醫院確診S-ALCL病例51例,常規形態觀察,複習及補充必要免疫組化標記以覈實診斷.採用SP法檢測ALK-1蛋白及細胞毒相關蛋白TIA-1和granzyme B的錶達.收集臨床資料併完善隨訪.結果 51例S-ALCL中,36例(63%)ALK-1蛋白暘性.47例S-ALCL中20例(42.55%)granzyme B蛋白暘性.28例行TIA-1蛋白檢測,22例(81.48%)暘性.51例中有隨訪資料者共44例(86.27%),生存時間0.5～66箇月.ALK-1暘性病例、granzyme B陰性病例預後較好.而TIA-1的錶達與預後無關.COX比例風險迴歸分析錶明ALK-1、granzyme B的錶達及Ann-Arbor分期對預後有統計學意義(P＜0.05).結論 ALK-1與granzyme B均是獨立的預後指標,有助于S-ALCL病例的預後判斷.
목적 연구원발계통형간변성대세포림파류(S-ALCL)간변성림파류격매(ALK-1)단백급세포독성상관단백TIA-1화granzyme B표체정황,탐토기여예후적관계.방법 수집북경대학의학부병이학계림파류연구실급북경인동의원학진S-ALCL병례51례,상규형태관찰,복습급보충필요면역조화표기이핵실진단.채용SP법검측ALK-1단백급세포독상관단백TIA-1화granzyme B적표체.수집림상자료병완선수방.결과 51례S-ALCL중,36례(63%)ALK-1단백양성.47례S-ALCL중20례(42.55%)granzyme B단백양성.28례행TIA-1단백검측,22례(81.48%)양성.51례중유수방자료자공44례(86.27%),생존시간0.5～66개월.ALK-1양성병례、granzyme B음성병례예후교호.이TIA-1적표체여예후무관.COX비례풍험회귀분석표명ALK-1、granzyme B적표체급Ann-Arbor분기대예후유통계학의의(P＜0.05).결론 ALK-1여granzyme B균시독립적예후지표,유조우S-ALCL병례적예후판단.
Objective To study the expressions of anaplastic lymphoma kinase (ALK-1) and cytotoxic proteins in primary systemic anaplastic large cell lymphoma (S-ALCL) and their relationship with clinical outcome. Methods 51 S-ALCL cases were collected from Lymphoma Lab of Peking University Health Science Centre & Peking Children's Hospital. The morphologic characteristics were studied under routine microscope, and essential immunohistochemical stainings were performed and reviewed to confirm the diagnosis of S-ALCL. Immunohistochemical stainings for ALK-1 and cytotoxic proteins (TIA-1 & granzyme B) were performed using standard SP method. Patients related clinical data including follow-up materials were collected. Results Survival time of 44 cases with completely clinical follow up materials ranged from 0.5～66months. 36 out of 51 cases(37 %) was positive for ALK-1 protein. While 20 cases out of 47 S-ALCL cases ( 42.55 % ) positive for granzyme B and 22 out of 28 cases (81.48 %) were positive for TIA-1. The prognosis of patients with ALK-1 protein positive and granzyme B negative expression was better, but TIA-1 expression might have nothing to do with clinical outcome (P＞0.05). In addition, multivariate analysis confirmed that ALK-1 protein expression, granzyme B protein expression and Ann-Arbor stage system were possible for prognosis(P＜0.05), Conclusion Expression of ALK-1 and granzyme B protein expression may serve as two independent prognostic predictors in S-ALCL patients.
